Abstract

Epstein-Barr virus (EBV)-associated lymphoproliferative disorders (LPDs) sometimes occur following Anti-thymocyte globulin (ATG) administration for allogenic stem cell transplantation but are rare in aplastic anemia (AA) patients. A 55-year-old woman with AA following ATG developed refractory fever and was diagnosed with EBV-LPD. She was successfully treated with weekly rituximab monotherapy; however, she developed EBV encephalitis. She was admitted to the intensive care unit and finally recovered from unconsciousness. EBV-LPD should be considered after ATG for AA when symptoms appear. Because EBV-LPD following ATG for AA can rapidly progress, weekly monitoring of EBV-DNA and early intervention may be necessary.

Key words: Anti-thymocyte globulin, Epstein-Barr virus, aplastic anemia, encephalitis, rituximab, lymphoproliferative disorder

(DOI: 10.2169/internalmedicine.56.7722)

Introduction

Epstein-Barr virus (EBV) is a gammaherpesvirus that latently infects approximately 90% of human adults. The main targets of EBV infection are naïve B-cells, which are activated to proliferating blasts. Infection by EBV and the spread of EBV are controlled by host antibodies and cytotoxic T lymphocytes (CTLs). However, the host immune system cannot completely eliminate EBV; therefore, infected B cells can persist at low levels (1).

Anti-thymocyte globulin (ATG) is a rabbit-derived polyclonal antibody with a high affinity for T cells and leukocyte surface antigens. ATG reduces the levels of antigen-reactive T cells in the peripheral blood. Impairment of the CTL response is associated with abnormal proliferation of B cells. Post-transplant lymphoproliferative disorders (PTLDs) are lymphoid or plasmatic proliferation disorders that develop after solid organ transplantation or allogeneic hematopoietic stem cell transplantation (allo-HSCT) because of immunosuppression (2). ATG-containing conditioning regimens have been reported to increase the risk of PTLDs (3-5). The recommended strategy for the prevention of PTLDs is the reduction of immunosuppression with or without preemptive rituximab therapy, based on regular monitoring of EBV deoxyribonucleic acid (EBV-DNA) loads in peripheral blood. Preemptive rituximab therapy has been reported to prevent the development of PTLDs in ap-

1Department of Oncology and Hematology, The Jikei University School of Medicine, Japan, 2Research Center for Medical Science, Core Research Facilities for Basic Science (Molecular Genetics), The Jikei University School of Medicine, Japan and 3Department of Oncology and Hematology, The Jikei University School of Medicine, Daisan Hospital, Japan

Received for publication May 18, 2016; Accepted for publication July 3, 2016

Correspondence to Dr. Keisuke Aiba, aiba@jikei.ac.jp
EBV-LPD and EBV encephalitis following ATG therapy

port a case of a patient with aplastic anemia who developed treatment options for EBV-LPDs and PTLDs. We herein re-

without combination chemotherapy have been reported as

anemia are rapidly progressive and often fatal. Reduction of disorders (EBV-LPDs) following ATG therapy for aplastic

have been reported (13-22). EBV-associated lymphoproliferative

come of EBV encephalitis following ATG therapy has not

munosuppressive therapy for aplastic anemia have been re-

mab (11, 12).

rning treatment using rabbit ATG was reportedly more severe

tients with aplastic anemia, the reactivation of EBV follow-

were used for cord blood, and haploidentical transplant (6). In pa-

ond allo-HSCT, the presence of graft-versus-host disease, the

risk factors for PTLD following allo-SCT, the risk factors include a T

P

sibling donor, if available, for patients <40 year of age or with no HLA-identical sibling donor (9). In the setting of allo-HSCT, ATG is associated with an increased risk of EBV reactivation and PTLD (10). Scheinberg et al. reported that EBV reactivation occurred in 100% of EBV-seropositive patients after receiving rabbit ATG at a dose of 3.5 mg/kg with cyclosporin A (CsA) therapy for severe aplastic anemia (11).

The risk factors for EBV-LPD following treatment for aplastic anemia have not yet been determined. With regard to PTLD following allo-SCT, the risk factors include a T cell depletion treatment regimen, patient age >50 years, second allo-HCT, the presence of graft-versus-host disease, the use of cord blood, and haploidentical transplant (6). In pa-

patients with aplastic anemia, the reactivation of EBV follow-

ing treatment using rabbit ATG was reportedly more severe than that following treatment using horse ATG or alemtuzumab (11, 12).

Ten cases of EBV reactivation and/or LPDs following immuno-
suppressive therapy for aplastic anemia have been re-

ported in the literature. However, to our knowledge, the out-

come of EBV encephalitis following ATG therapy has not been reported (13-22). EBV-associated lymphoproliferative disorders (EBV-LPDs) following ATG therapy for aplastic anemia are rapidly progressive and often fatal. Reduction of immunosuppression and rituximab monotherapy with or without combination chemotherapy have been reported as treatment options for EBV-LPDs and PTLDs. We herein re-

port a case of a patient with aplastic anemia who developed EBV-LPD and EBV encephalitis following ATG therapy

who was successfully treated using rituximab monotherapy.

Case Report

A 55-year-old woman was referred to our hospital because of pancytopenia. Her medical history included lumpectomy and adjuvant radiochemotherapy for breast cancer at 49 years of age. Because her peripheral blood count had gradually decreased, she was admitted to our department in May 2012. On a physical examination, the patient had conjunctival pallor and local purpura of her lower legs. Laboratory studies revealed pancytopenia with an absolute neutrophil count of 0.4×10^9/L, reticulocyte count of 47.8×10^9/L, and platelet count of 17×10^9/L. Bone marrow aspiration and biopsy showed severely hypoplastic marrow with 90% of the normal tissue replaced by adipose tissue with no blasts or mature cells. There were no atypical or malignant cells present. Magnification×100. Hematoxylin and Eosin staining.

Figure 1. Photomicrograph of the patient’s bone marrow smear at the time of diagnosis of aplastic anemia. Ninety percent of the normal bone marrow tissue was replaced by adipose tissue with no blasts or mature cells. There were no atypical or malignant cells present. Magnification×100. Hematoxylin and Eosin staining.
Figure 2. Clinical course of the patient. Forty-five days after ATG initiation, the serum LDH level was elevated to more than 3,000 U/L, and the serum EBV-DNA level increased to 1.1x10^6 copies/10^6 cells. Following rituximab therapy, these levels rapidly decreased. Rituximab was administered once a week for 8 weeks.

Figure 3. Abdominal computed tomography before the initiation of rituximab. Abdominal computed tomography demonstrated hepatosplenomegaly, increased thickness of the gallbladder wall, and multiple enlarged abdominal lymph nodes.

clonality of EBV-DNA in her peripheral blood by Southern blotting hybridization (Fig. 4). Following a second cycle of rituximab, she recovered from respiratory failure and was extubated.

Although her general status and laboratory data had improved, she suddenly fell unconscious three days after the second cycle of rituximab. Cranial T2-weighted MRI and fluid-attenuated inversion recovery (Fig. 5) showed high-intensity lesions in her cerebral cortex. A polymerase chain reaction (PCR) analysis for herpes simplex virus 1, 2 (HSV-1, 2), EBV, human herpes virus 6 (HHV-6), varicella zoster virus (VZV), and cytomegalovirus (CMV) was performed using the cerebrospinal fluid (CSF), and EBV-DNA was detected in the CSF sample. After EBV encephalitis with LPD was diagnosed, we administered ganciclovir and intravenous immunoglobulin (IVIG). As shown in Fig. 2, a real-time PCR analysis showed that the serum EBV-DNA level had rapidly decreased, and she regained consciousness. After eight subsequent courses of rituximab treatment, the EBV-DNA loads decreased below the detection limit, and the symptoms of EBV-LPDs and EBV encephalitis disappeared. A CT scan also revealed that there was no evidence of hepato-
The peak incidence of early PTLDs occurs 6-12 months following allo-HSCT (24). EBV-LPDs in patients with aplastic anemia may occur earlier than in patients with PTLDs. Therefore, it may be reasonable to begin monitoring within a week after ATG initiation.

With regard to allo-HSCT, patients with EBV reactivation and sufficient T cells improved only by reduction of immunosuppression (25). Among patients who developed PTLDs following allo-HSCT, the response rate for ATG was 84%, whereas the rate was only 61% without a reduction of immunosuppression (26). Our patient did not improve following reduction of immunosuppression; therefore, an anticancer agent was administered. This indicates that the reduction of immunosuppression following the development of LPDs may be less effective for EBV-LPDs after ATG than for PTLDs, which may be partly because EBV-LPDs following ATG for aplastic anemia generally develop before T cell reconstitution.

Other EBV-associated diseases sometimes concurrently develop with PTLDs. Three major EBV end-organ diseases in recipients of allo-HSCT are pneumonitis, encephalitis/myelitis, and hepatitis (27). Reportedly, EBV-associated diseases are more refractory to rituximab than other agents (27). The MRI features of central nervous system (CNS)-involved PTLD that develop after solid-organ transplantation are multiple contrast-enhancing, intra-axial lesions associated with extensive peritumoral edema (28). CNS-involved PTLD masses are generally hypercellular, appearing hypo- to isointense on both plain T1- and T2-weighted MRI (29). Unlike CNS-involved PTLD, EBV encephalitis is reported to appear hyperintense on plain T2-weighted and fluid-attenuated inversion recovery (FLAIR) MRI (30). Because EBV-DNA was detected in the CSF and cranial MRI T2-weighted and FLAIR revealed a high-intensity cerebral cortex without masses or peritumoral edema, we suspected

**Discussion**

This case report demonstrated that EBV-associated LPD with EBV encephalitis following ATG therapy for aplastic anemia can be successfully treated with rituximab. This finding may have implications for future patient treatment because it suggests that early detection of EBV-DNA and EBV reactivation may be beneficial for patients receiving ATG treatment for aplastic anemia.

Ten previously reported cases of EBV reactivation and/or LPD following immunosuppressive therapy for aplastic anemia from the literature can be compared with this case, although no case included EBV encephalitis (13-22). As shown in Table, six previously reported patients with LPD achieved a complete response (CR) with reduction of immunosuppression and/or combination chemotherapy (14, 16-19, 22). The initial signs of EBV-LPDs are a fever, general fatigue, loss of appetite, lymphadenopathy, hepatosplenomegaly, appearance of atypical lymphocytes in peripheral blood, and/or elevation of serum LDH (13-22). In our case, the cessation of immunosuppressive agents did not improve the symptoms of EBV-LPD; however, rituximab monotherapy resulted in a CR.

Weekly monitoring of the peripheral EBV-DNA load is recommended for high-risk patients following allo-HSCT (23). The peak incidence of early PTLDs occurs 6-12 months following allo-HSCT (24).

![Southern blot analysis](image1.png)

**Figure 4.** Southern blot analysis demonstrated monoclonality of the EBV-infected cells. M' represents the size marker of the DNA; No. 1 is the positive control, No. 2 is the negative control, and No. 3 is the patient’s peripheral blood sample.

![Cranial MRI](image2.png)

**Figure 5.** Cranial magnetic resonance imaging (MRI) fluid attenuation inversion recovery imaging. Cranial MRI fluid attenuation inversion recovery imaging revealed high-intensity lesions in the cerebral cortex, in keeping with a diagnosis of viral (EBV) encephalitis.
Figure 6. Abdominal computed tomography after the eight cycles of rituximab. A CT scan revealed that there was no evidence of hepatosplenomegaly, enlarged gallbladder, or abdominal lymphadenopathy after treatment with rituximab.

Table. Previous Case Reports of Lymphoproliferative Disorders Following Immunosuppressive Treatment for Aplastic Anemia.

<table>
<thead>
<tr>
<th>Age/sex</th>
<th>Dose and a type of ATG treatment</th>
<th>Time to appearance of initial symptoms of EBV-LPD following ATG</th>
<th>Time to diagnosis</th>
<th>Diagnosis</th>
<th>Peak EBV-viral loads</th>
<th>Treatment for LPD</th>
<th>Outcome</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>36/M</td>
<td>0.75 mg/kg/d for 9 days</td>
<td>9 days</td>
<td>EBV-LPDs</td>
<td>4 × 10^6 copies/mL, 3.3 × 10^6 copies/10^9 WBC</td>
<td>Rituximab, CPM</td>
<td>Died</td>
<td>[13]</td>
<td></td>
</tr>
<tr>
<td>42/F</td>
<td>Rabbit, 12.5 mg/kg/d</td>
<td>2 weeks</td>
<td>DLBCL</td>
<td></td>
<td></td>
<td>CR</td>
<td>[14]</td>
<td></td>
</tr>
<tr>
<td>54/M</td>
<td>Rabbit, 3.75 mg/kg/d for 5 days</td>
<td>26 days</td>
<td>EBV-LPDs</td>
<td></td>
<td></td>
<td>Died</td>
<td>[15]</td>
<td></td>
</tr>
<tr>
<td>38/M</td>
<td>Rabbit, 3.5 mg/kg/d for 1 day</td>
<td>19 days</td>
<td>Infectious mononucleosis</td>
<td>30,000/150,000 cells</td>
<td>Cessation of CsA, Rituximab</td>
<td>CR</td>
<td>[16]</td>
<td></td>
</tr>
<tr>
<td>55/M</td>
<td>Rabbit, 3.75 mg/kg/d for 5 days</td>
<td>26 days</td>
<td>EBV-LPDs</td>
<td>7.9 × 10^6 copies/mL</td>
<td>Rituximab</td>
<td>CR</td>
<td>[17]</td>
<td></td>
</tr>
<tr>
<td>55/M</td>
<td>Rabbit, 3.75 mg/kg/d for 5 days</td>
<td>5 days</td>
<td>Infectious mononucleosis</td>
<td>140 copies/10^9 WBC</td>
<td>Cessation of CsA</td>
<td>CR</td>
<td>[18]</td>
<td></td>
</tr>
<tr>
<td>46/F</td>
<td>Rabbit, 3.75 mg/kg/d for 5 days</td>
<td>5 days</td>
<td>EBV-LPDs</td>
<td>4 × 10^6 copies/mL</td>
<td>Cessation of CsA, Rituximab</td>
<td>Died</td>
<td>[19]</td>
<td></td>
</tr>
<tr>
<td>38/M</td>
<td>Rabbit, 3.5 mg/kg/d for 1 day</td>
<td>19 days</td>
<td>EBV-LPDs</td>
<td>1.1 × 10^6 copies/10^6 cells</td>
<td>Cessation of CsA, Rituximab</td>
<td>CR</td>
<td>[20]</td>
<td></td>
</tr>
<tr>
<td>55/F</td>
<td>Rabbit, 3.75 mg/kg/d for 5 days</td>
<td>19 days</td>
<td>EBV-LPDs</td>
<td>4 × 10^6 copies/10^6 cells</td>
<td>Cessation of CsA, Rituximab</td>
<td>CR</td>
<td>[21]</td>
<td></td>
</tr>
<tr>
<td>55/F</td>
<td>Rabbit, 3.75 mg/kg/d for 5 days</td>
<td>19 days</td>
<td>EBV-LPDs</td>
<td>4 × 10^6 copies/10^6 cells</td>
<td>Cessation of CsA, Rituximab</td>
<td>CR</td>
<td>[22]</td>
<td></td>
</tr>
<tr>
<td>46/F</td>
<td>Rabbit, 3.75 mg/kg/d for 5 days</td>
<td>26 days</td>
<td>EBV-LPDs</td>
<td>4 × 10^6 copies/10^6 cells</td>
<td>Cessation of CsA, Rituximab</td>
<td>CR</td>
<td>[23]</td>
<td></td>
</tr>
<tr>
<td>55/F</td>
<td>Rabbit, 3.75 mg/kg/d for 5 days</td>
<td>28 days</td>
<td>EBV-LPDs</td>
<td>4 × 10^6 copies/10^6 cells</td>
<td>Cessation of CsA, Rituximab</td>
<td>CR</td>
<td>[24]</td>
<td></td>
</tr>
<tr>
<td>38/M</td>
<td>Rabbit, 3.5 mg/kg/d for 1 day</td>
<td>36 days</td>
<td>EBV-LPDs</td>
<td>4 × 10^6 copies/10^6 cells</td>
<td>Cessation of CsA, Rituximab</td>
<td>CR</td>
<td>[25]</td>
<td></td>
</tr>
</tbody>
</table>


Time to diagnosis indicates the duration from Day 1 on recent immunosuppression therapy to the appearance of the first symptom of LPD.

Our patient of having EBV encephalitis and not EBV-LPD with CNS involvement.

In conclusion, we reported a case of EBV-LPD with EBV encephalitis following ATG therapy in a patient with aplastic anemia who was successfully treated using rituximab. This case demonstrates that, in patients with aplastic anemia who are treated using ATG therapy, the initial symptoms of EBV-LPD should be considered. Because EBV-LPD following treatment for aplastic anemia progresses more rapidly than PTLD, weekly monitoring of EBV-DNA may be necessary. If EBV-LPD develops during treatment for aplastic anemia, a reduction in immunosuppressive treatment may be insufficient; therefore, preemptive treatment using rituximab should be considered.

The authors state that they have no Conflict of Interest (COI).

Consent for publication

Informed consent was obtained form the patient for publication.

Acknowledgement

We thank Ms. Yumiko Inui (Kobe University) for the useful advice regarding our medical practice.

Author contributions

KM, SY, and HY were the physicians in charge of the case. All of the authors contributed to the composition of this article and have read and approved the final manuscript.

References


The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).

© 2017 The Japanese Society of Internal Medicine
http://www.naika.or.jp/imonline/index.html